Innate Pharma SA Comprehensive Income
Innate Pharma SA (IPHA) reported Comprehensive Income of -EUR 48.09 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-04-01.
Financial Statements › Income Statement › Unrealized Gains
ifrs-full:ComprehensiveIncome · last filed 2026-04-01
| Period end | Comprehensive Income 6 month | Comprehensive Income 12 month |
|---|---|---|
| 2025-12-31 | -48.09M EUR 20-F · filed 2026-04-01 | |
| 2025-06-30 | -20.18M EUR 6-K · filed 2025-09-17 | |
| 2024-12-31 | -49.94M EUR 20-F · filed 2026-04-01 | |
| 2024-06-30 | -24.91M EUR 6-K · filed 2025-09-17 | |
| 2023-12-31 | -6.90M EUR 20-F · filed 2026-04-01 | |
| 2023-06-30 | 1.97M EUR 6-K · filed 2024-09-12 | |
| 2022-12-31 | -57.74M EUR 20-F · filed 2025-04-30 | |
| 2022-06-30 | 6.10M EUR 6-K · filed 2023-09-14 | |
| 2021-12-31 | -52.71M EUR 20-F · filed 2024-04-04 | |
| 2021-06-30 | -23.33M EUR 6-K · filed 2022-09-15 | |
| 2020-12-31 | -63.96M EUR 20-F · filed 2023-04-06 | |
| 2020-06-30 | -10.48M EUR 6-K · filed 2021-09-15 | |
| 2019-12-31 | -20.13M EUR 20-F · filed 2022-04-04 | |
| 2018-12-31 | 2.42M EUR 20-F · filed 2021-04-27 | |
| 2017-12-31 | -47.70M EUR 20-F · filed 2020-04-24 |